Charles McDermott

Chairman, President & CEO

Charles (Charlie) McDermott has more than 24 years of experience in the life sciences industry and has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning, and executive management. Most recently Mr. McDermott was President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc. While at Impact, Mr. McDermott raised more than $110 million in private equity and royalty financing to fully fund the development and commercialization of fedratinib for the treatment of serious hematological malignancies. Impact was acquired by Celgene in 2018 for $1.1 billion upfront and up to $7 billion overall, if all contingent payments are realized. Prior to joining Impact, Mr. McDermott was President and Chief Business Officer of Kala Pharmaceuticals, Inc. Mr. McDermott helped lead the transformation of Kala from a private pre-clinical stage company to a pre-commercial stage public company. To this end, Mr. McDermott helped raise ~$190 million via private equity, debt, and an initial public offering. In August of 2018, Kala received NDA approval for Inveltys™, an internally developed drug for ocular indications. Before Joining Kala, Mr. McDermott worked at Allergan as Vice President, Global Business Development for the Eye Care and Drug Delivery business units. At Allergan, Mr. McDermott led efforts to license and acquire a variety of technologies and therapeutics including Lastacaft™, Acuvail™, Restasis® MultiDose™, Latisse™, and Abicipar. Before Joining Allergan, Mr. McDermott was Associate Director of Business Development at deCODE genetics (and before that he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Mr. McDermott has a B.A. in biochemistry and molecular biology from UC Santa Cruz, a M.A. in molecular, cellular, and developmental biology from UC Santa Barbara, and a MBA from the University of San Diego.

Paulo Rangel

Chief Business Officer, Co-founder, and Director

Paulo Rangel brings 25 years experience in the pharmaceutical and related industries in both small and large companies. Before Primmune, Mr. Rangel was President & CEO and Co-founder of Evince Biosciences, a precursor to Primmune Therapeutics. Before Evince, Mr. Rangel was a Partner at ProPharma Partners International, an international consulting group. He concentrated on working with biopharmaceutical and medical device companies on worldwide in- and out- licensing, valuations, business plans and market research. Before ProPharma, Mr. Rangel was Head of Global Business Development at Besins Healthcare, a global pharmaceutical company with products targeted at women’s and men’s health. Mr. Rangel was a founder of, and key executive in, two medical device start-ups, Lasercure Sciences and 5i Sciences (now Sommetrics). In those positions, he completed the financing, clinical studies and collaborations, and was responsible for all intellectual property. Mr. Rangel has filled key roles in a number of other biotechnology companies and worked at Amgen and Hybritech/Lilly early in his career. Mr. Rangel received a B.A. in chemistry and biochemistry from the UC San Diego and an MBA from The Fuqua School of Business at Duke University.

James Appleman, Ph.D.

SVP, R&D and CSO
Co-founder, Director

James (Jim) Appleman, Ph.D. is SVP, R&D and CSO, Co-founder, Director of Primmune. Dr. Appleman brings to Primmune nearly thirty years of experience in building successful drug discovery organizations. He has been an advisor to biotech, hi-tech and diagnostic firms. Dr. Appleman is a co-founder of eFFECTOR Therapeutics ($45M original Series A funding) where he established both the technology base and bioinformatics infrastructure to support eFFECTOR’s unique programs targeting dysregulated mRNA translation. He previously served as Senior Vice President, Research and Chief Scientific Officer at Anadys Pharmaceuticals, Inc. where he played a pivotal role in the business process culminating in the acquisition of Anadys for $230M (256% premium to market cap) by Roche Pharma and in the invention, characterization and clinical development of the company's internally discovered drug candidates setrobuvir and ANA773. ANA773 is a novel TLR7 (toll-like receptor 7) agonist originally intended for the treatment of cancer and hepatic viral diseases. Prior to joining Anadys, Dr. Appleman held positions at Gensia, Inc. and it’s subsidiary Metabasis Therapeutics and was a faculty member at St. Jude Children's Research Hospital. He received a Ph.D. in biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

At Anadys, Dr. Appleman personally led the ANA773 team from conception through realization (characterization of target-mediated biology, selection of medicinal chemistry starting points, lead optimization, candidate selection, preclinical development, clinical proof of concept). The combination of practical experience with this TLR7 agonist and other activators of innate immunity coincidental with the emergence of immunotherapy as paramount in the successful treatment of cancer places Primmune at the very heart of the most compelling area of drug discovery and development today.

Stephen Webber, Ph.D.

Vice President, Medicinal Chemistry, and Co-founder

Stephen E. Webber Ph.D. is a Primmune Therapeutics co-founder and advisor and expert in the discovery of TLR7 agonists. He is currently Executive Director of Medicinal Chemistry at Polaris Pharmaceuticals, where he is responsible for the discovery and synthesis of small molecule cancer therapeutics utilizing structure-based drug design techniques. Prior to joining Polaris, Dr. Webber was a co-founder and Director of Medicinal Chemistry at eFFECTOR Therapeutics, a company devoted to the discovery and development of translation regulators for cancer. At eFFECTOR, Dr. Webber’s responsibilities included building and managing a Medicinal Chemistry group, laboratories, and chemistry outsourcing, and performing structure-based drug design. Before this position, Dr. Webber was in charge of leading the discovery chemistry efforts at Anadys Pharmaceuticals, where he served in various senior level positions until the company was acquired by Roche. At Anadys, Dr. Webber discovered and co-invented several therapeutically important antiviral and anticancer small molecules, including clinical candidate setrobuvir, and TLR7 agonists ANA-975 and ANA-773. Dr. Webber also discovered rucaparib, which was licensed to Clovis Oncology by Pfizer and was approved by the FDA to treat ovarian cancer (marketed as Rubraca®). It is currently the subject of several Phase 2 and 3 clinical studies in other cancers in patients with the BRCA, or BRCA-like mutations. Dr. Webber’s industrial career extends back to Agouron Pharmaceuticals Inc., joining the company in 1987 at its inception. Dr. Webber received his B.S. from Philadelphia University (now part of Thomas Jefferson University) and his Ph.D. from the University of Pennsylvania.

Todd Harris, Ph.D.


Todd Harris, Ph.D. has served as a member of our board of directors since the company founding in Oct. 2017. He has been a member of the board of directors of Sienna Biopharmaceuticals since 2010 and the Head of Corporate Development since January 2016. Dr. Harris was the founder of Sienna Labs, Inc. and served as its Chief Executive Officer from July 2010 until January 2016. Previously, from 2008 to 2013, Dr. Harris was a consultant at McKinsey & Company in the Health Care Practice Division. Between 2006 and 2008, Dr. Harris held a graduate fellowship with the National Institute of Health. Dr. Harris received a B.S. in Engineering from Brigham Young University, an M.S. in Bioengineering from the University of California, San Diego, and a Ph.D. in Medical Engineering and Medical Physics from the Massachusetts Institute of Technology.

Scott Morenstein


Scott Morenstein is a Managing Director and Portfolio Manager at CAM Capital where he has led the firm's investment strategy in both private and public biotech companies since 2013.  CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. Prior to joining CAM Capital in 2013, Mr. Morenstein was a Partner at Valence Advantage Life Sciences Fund and Principal at Caxton Advantage Venture Partners, life science focused venture capital firms affiliated with Caxton Associates, which he joined in 2007.  Prior to Caxton Advantage, Scott was an investment banker and research analyst at Seaview Securities and Lehman Brothers from 2000-2005. Mr. Morenstein served as a Director of and CAM was the largest investor in Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. He was nominated a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X Pharmaceutical's Board until its acquisition by Cephalon. He currently serves as a Director of Molecular Templates (Nasdaq: MTEM), Antios Therapeutics (private) and Velicept Therapeutics (private). Mr. Morenstein received an MBA from Harvard Business School and a BA from the University of Pennsylvania in the Biological Basis of Behavior with a concentration in the Physiology of Neural Systems.